Capital Research Global Investors
CADX

Capital Research Global Investors’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Capital Research Global Investors’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-6,113,768
Closed -$55.3M – 445
2013
Q4 		$55.3M Hold
6,113,768
– – 0.02% 329
2013
Q3 		$38.6M Sell
6,113,768
-284,405
-4% -$1.81M 0.02% 361
2013
Q2 		$43.6M Buy
+6,398,173
New +$44.6M 0.02% 330

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Capital Research Global Investors's CADX Position: Q1 2014 in Review

Capital Research Global Investors sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 6,113,768 shares — an estimated $55.3M sold.

Capital Research Global Investors first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $55.3M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Capital Research Global Investors reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Capital Research Global Investors sold 6,113,768 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $55.3M.
  • Capital Research Global Investors first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Capital Research Global Investors's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $55.3M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Capital Research Global Investors's 13F filing for Q1 2014, filed 15 May 2014.